Search Results for: IMMUNOTHERAPY RESEARCH The Shift Toward
Articles
IMMUNOTHERAPY RESEARCH - The Shift Toward Combination Therapies March 30, 2016
Jean Pierre Wery, PhD, indicates immunotherapy in combination with traditional treatments has the potential for becoming a more effective alternative to the current standard of care. These types of combination therapies are currently under investigation and appear to have synergistic effects compared to the use of one therapy alone.
Evonik & Stanford University Sign Research Collaboration: Evonik to Market & Develop New Drug Delivery Platform for mRNA & Gene Therapy June 16, 2021
Evonik is working with Stanford University on a technology to deliver mRNA to tissues and organs that goes beyond the capabilities of lipid nanoparticles (LNPs)…..
F-star Announces Strategic Collaboration & License Agreement With Takeda July 5, 2023
F-star Therapeutics, an invoX company, recently announced it has entered into a strategic discovery collaboration and licensce agreement with….
Pharmaceutical Contract Manufacturing Market is Expected to Reach $171.3 Billion April 10, 2023
The Pharmaceutical Contract Manufacturing industry is expected to continue to grow in the near future due to a number of...SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Understanding Critical Attributes Earlier in Development Leads to a More Robust Drug Product June 1, 2022
Contributor Cindy H. Dubin speaks with industry leaders on how drug sponsors and CDMOs are collaborating earlier, and highlights how third-party contractors are navigating material shortages and how the industry is shifting to address different therapeutic targets and molecules, such as mRNA.
Prothena Receives FDA Fast Track Designation for Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease April 26, 2022
Prothena Corporation plc recently announced the US FDA has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta...Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease March 28, 2022
Prothena Corporation plc recently announced the US FDA has cleared the investigational new drug (IND) application for PRX012, a potential...MARKET BRIEF - Alzheimer’s Disease Market Report (2016-2026) October 2, 2018
Akiko Fukui, MSc, indicates that amid several failures, the AD pipeline is large and consists of many novel mechanisms, which makes it an exciting market undergoing rapid changes despite its high risk.
CLINICAL TRIALS - Maximizing Immuno-Oncology Clinical Trial Success June 4, 2018
Luke S. Gill, MSc, MBA, believes understanding and overcoming various challenges in the development of immunotherapeutic agents will be critical to clinical trial success and, ultimately, market approval.
11/01/2011 October 27, 2011
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing...
